- Previous Close
15.59 - Open
15.58 - Bid 15.27 x 400
- Ask 15.34 x 100
- Day's Range
15.10 - 15.58 - 52 Week Range
13.39 - 42.08 - Volume
217,307 - Avg. Volume
2,288,830 - Market Cap (intraday)
1.305B - Beta (5Y Monthly) 1.44
- PE Ratio (TTM)
25.53 - EPS (TTM)
0.60 - Earnings Date Feb 25, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.86
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
www.progyny.com563
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PGNY
View MorePerformance Overview: PGNY
Trailing total returns as of 12/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PGNY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PGNY
View MoreValuation Measures
Market Cap
1.33B
Enterprise Value
1.11B
Trailing P/E
25.98
Forward P/E
9.93
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.33
Price/Book (mrq)
3.05
Enterprise Value/Revenue
0.97
Enterprise Value/EBITDA
16.20
Financial Highlights
Profitability and Income Statement
Profit Margin
5.03%
Return on Assets (ttm)
5.90%
Return on Equity (ttm)
12.05%
Revenue (ttm)
1.14B
Net Income Avi to Common (ttm)
57.27M
Diluted EPS (ttm)
0.60
Balance Sheet and Cash Flow
Total Cash (mrq)
235.72M
Total Debt/Equity (mrq)
4.48%
Levered Free Cash Flow (ttm)
144.85M